ENS 52035: Difference between revisions
Jump to navigation
Jump to search
StriderTol (talk | contribs) (Created page by program invented by Mark Hawes) |
StriderTol (talk | contribs) (Created page by program invented by StriderTol) |
||
| Line 16: | Line 16: | ||
| event date = 06/17/2016 CDT | | event date = 06/17/2016 CDT | ||
| last update date = 06/22/2016 | | last update date = 06/22/2016 | ||
| title = Agreement State Report - Contamination | | title = Agreement State Report - Contamination of Brachytherapy Patient | ||
| event text = The following was received from Wisconsin via email: | | event text = The following was received from Wisconsin via email: | ||
On Friday, June 17, 2016, a licensee discovered contamination on a package that was used to ship I-125 prostate brachytherapy seeds. The post procedure survey of the packaging revealed elevated levels of radiation. After wipes were taken, the licensee determined that there was I-125 contamination on the inside of the packaging. There was no other contamination in the operating room. The licensee had the patient return to the facility to perform a urine bioassay. The bioassay revealed elevated levels of I-125 in the patient's urine. However further analysis will be required to determine activity concentrations. The licensee has also administered Lugols solution to the patient to block the thyroid. The department and the licensee are still collecting data to determine if this is a medical event. Site visits and updates will be performed as needed. | On Friday, June 17, 2016, a licensee discovered contamination on a package that was used to ship I-125 prostate brachytherapy seeds. The post procedure survey of the packaging revealed elevated levels of radiation. After wipes were taken, the licensee determined that there was I-125 contamination on the inside of the packaging. There was no other contamination in the operating room. The licensee had the patient return to the facility to perform a urine bioassay. The bioassay revealed elevated levels of I-125 in the patient's urine. However further analysis will be required to determine activity concentrations. The licensee has also administered Lugols solution to the patient to block the thyroid. The department and the licensee are still collecting data to determine if this is a medical event. Site visits and updates will be performed as needed. | ||
Latest revision as of 21:44, 1 March 2018
| Where | |
|---|---|
| Aspirus-Wausau Hospital Wausau, Wisconsin (NRC Region 3) | |
| License number: | 073-1342-01 |
| Organization: | Wisconsin Radiation Protection |
| Reporting | |
| Agreement State | |
| Time - Person (Reporting Time:+132.77 h5.532 days <br />0.79 weeks <br />0.182 months <br />) | |
| Opened: | Krista Kuhlman 17:46 Jun 22, 2016 |
| NRC Officer: | Daniel Mills |
| Last Updated: | Jun 22, 2016 |
| 52035 - NRC Website | |